Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5418-5424

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Manshouri, Taghi ^a   Luthra, Rajyalakshmi ^a   Estrov, Zeev ^a   Pierce, Sherry ^a   Richie, Mary Ann ^a   Borthakur, Gautam ^a   Konopleva, Marina ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA2A; ALPHA2A INTERFERON; JAK2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ADULT; AGED; ALLELE; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; BLURRED VISION; BONE MARROW BIOPSY; CLINICAL ASSESSMENT; CLONE; CYTOGENETICS; DEPRESSION; DIARRHEA; DIZZINESS; DNA EXTRACTION; DRUG DOSE REDUCTION; DRUG TARGETING; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HEMATOLOGY; HUMAN; INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PAIN; PHYSICAL EXAMINATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREGNANCY TEST; PRIORITY JOURNAL; PYROSEQUENCING; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THYROID FUNCTION TEST; TREATMENT RESPONSE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; HUMANS; INTERFERON ALFA-2A; JANUS KINASE 2; MIDDLE AGED; MUTATION; NEUTROPENIA; POLYCYTHEMIA VERA; POLYETHYLENE GLYCOLS; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949090770     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6075     Document Type: Article

References (34)

1. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005
2. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148, 2005
3. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
4. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397, 2005
5. Zhao R, Xing S, Li Z, et al: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792, 2005
6. Landolfi R, Di Gennaro L, Falanga A: Thrombosis in myeloproliferative disorders: Pathogenetic facts and speculation. Leukemia 22:2020-2028, 2008
7. Kiladjian JJ, Cassinat B, Turlure P, et al: High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037-2040, 2006
8. Jones AV, Silver RT, Waghorn K, et al: Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339-3341, 2006
9. Marchioli R, Finazzi G, Landolfi R, et al: Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224-2232, 2005
10. Cortelazzo S, Viero P, Finazzi G, et al: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990
11. Finazzi G, Barbui T: Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494-1502, 2008
12. Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91:616-622, 1998
13. Finazzi G, Ruggeri M, Rodeghiero F, et al: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 110:577-583, 2000
14. Kiladjian JJ, Chomienne C, Fenaux P: Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22:1990-1998, 2008
15. Quintás-Cardama A, Kantarjian HM, Giles F, et al: Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32:409-416, 2006
16. Lipton JH, Khoroshko N, Golenkov A, et al: Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 48:497-505, 2007
17. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459-468, 2007
18. Barosi G, Birgegard G, Finazzi G, et al: Response criteria for essential thrombocythemia and polycythemia vera: Result of a European Leukemia-Net (ELN) consensus conference. Blood 113:4829-4833, 2009
19. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45, 2005
20. Najean Y, Rain JD: Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370-3377, 1997
21. Besses C, Alvarez-Larran A, Martinez-Aviles L, et al: Major hematological response is the main factor for achieving a major molecular response in JAK2V617F-positive essential thrombocythemia and polycythemia vera patients treated with hydroxyurea. Blood 112:660, 2008 (abstr)
22. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366: 1945-1953, 2005
23. Kiladjian JJ, Cassinat B, Chevret S, et al: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065-3072, 2008
24. Gangat N, Wolanskyj AP, McClure RF, et al: Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 21:270-276, 2007
25. Kiladjian JJ, Gardin C, Renoux M, et al: Longterm outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 4:198-207, 2003
26. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446-2452, 2007
27. Jones AV, Kreil S, Zoi K, et al: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168, 2005
28. Kiladjian J, Dupont S, Cassinat B, et al: Can peginterferon (IFN) α-2a eradicate JAK2V617F-positive bone marrow progenitors in polycythemia vera (PV)? Blood 112, 2008 (abstr 659)
29. Carlo-Stella C, Cazzola M, Gasner A, et al: Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70:1014-1019, 1987
30. Castello G, Lerza R, Cerruti A, et al: The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 87:621-623, 1994
31. Dudley JM, Westwood N, Leonard S, et al: Primary polycythaemia: Positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 75:188-194, 1990
32. Hino M, Futami E, Okuno S, et al: Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 66:161-162, 1993
33. Xiong Z, Yan Y, Liu E, et al: Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol 122:279-287, 2007
34. Talpaz M, Rakhit A, Rittweger K, et al: Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 11:6247-6255, 2005